Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for arterial stiffness in metabolic syndrome
IRCT20180619040151N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of curcumin in cardiometabolic risk (CMR), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Arterial stiffness. Started Jan 2019; status: completed.
02
Drugs
curcumin
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on IRCT20180619040151N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180619040151N2.